Five insights:
1. U.S. spinal implant revenues are expected to decrease by between 3 percent and 4 percent, compared to the same period for last year.
2. SeaSpine’s orthobiologics line is projected to decrease by between 1 percent and 2 percent year over year.
3. To maintain liquidity, the company is generating cost-savings in areas such as travel, consulting, events and clinical trials. All new hires have been frozen.
4. SeaSpine also plans to delay spending on product development and launches.
5. Keith Valentine, president and CEO of SeaSpine, pointed to the company’s balance sheet, which includes $92 million of net proceeds raised in January 2020, to help maintain operations during this challenging financial period.
SeaSpine’s cash position will enable it to “capitalize on any future growth opportunities when surgery volumes return to pre-pandemic levels,” according to Mr. Valentine.
More articles on devices:
Dr. Daniel Yoshor excited by new challenge at Penn Medicine
New York neurosurgeon recovers from COVID-19, volunteers at hospital ICU
Neurosurgeon, dentist’s 3D printed masks evolved production, being made worldwide: 5 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.